These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25884105)

  • 21. [Treatment of patients with chronic hepatitis B virus infect ion with lamivudine combined with famciclovir].
    Wang HF; Li L; Su HB; Ji W
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2003 Jun; 17(2):180-2. PubMed ID: 12870005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferon treatment with or without oral ganciclovir in HBeAg-negative chronic hepatitis B: a randomized study.
    Hadziyannis S; Alexopoulou A; Papakonstantinou A; Petraki K; Manesis E
    J Viral Hepat; 2000 May; 7(3):235-40. PubMed ID: 10849267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lamivudine vs lamivudine and interferon combination treatment of HBeAg(-) chronic hepatitis B.
    Yurdaydin C; Bozkaya H; Cetinkaya H; Sahin T; Karaoğuz D; Törüner M; Erkan O; Heper AO; Erden E; Bozdayi AM; Uzunalimoğlu O
    J Viral Hepat; 2005 May; 12(3):262-8. PubMed ID: 15850466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Three-phase sequential combined treatment with lamivudine and interferon in young patients with chronic hepatitis B.
    Marrone A; Zampino R; Portella G; Grimaldi M; Durante-Mangoni E; Santarpia L; Ruggiero G; Utili R
    J Viral Hepat; 2005 Mar; 12(2):186-91. PubMed ID: 15720534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequential treatment with lamivudine and interferon-alpha monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations.
    Shi M; Wang RS; Zhang H; Zhu YF; Han B; Zhang Y; Jin LJ; Yang ZJ; Xu YP
    J Antimicrob Chemother; 2006 Nov; 58(5):1031-5. PubMed ID: 16987866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis B genotypes in chronic hepatitis B and lamivudine therapy.
    Yuen MF; Tanaka Y; Lai CL
    Intervirology; 2003; 46(6):373-6. PubMed ID: 14688455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term lamivudine treatment for chronic hepatitis B in Japanese patients: a project of Kyushu University Liver Disease Study.
    Furusyo N; Takeoka H; Toyoda K; Murata M; Tanabe Y; Kajiwara E; Shimono J; Masumoto A; Maruyama T; Nomura H; Nakamuta M; Takahashi K; Shimoda S; Azuma K; Sakai H; Hayashi J
    World J Gastroenterol; 2006 Jan; 12(4):561-7. PubMed ID: 16489669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of the hepatitis B e antigen/anti-HBe status on the response to lamivudine.
    Suzuki F
    Intervirology; 2003; 46(6):339-43. PubMed ID: 14688449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis B e antigen seroconversion: effects of lamivudine alone or in combination with interferon alpha.
    Farrell G
    J Med Virol; 2000 Jul; 61(3):374-9. PubMed ID: 10861649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative.
    Sypsa VA; Mimidis K; Tassopoulos NC; Chrysagis D; Vassiliadis T; Moulakakis A; Raptopoulou M; Haida C; Hatzakis A
    Hepatology; 2005 Jul; 42(1):77-85. PubMed ID: 15962284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D.
    Erhardt A; Blondin D; Hauck K; Sagir A; Kohnle T; Heintges T; Häussinger D
    Gut; 2005 Jul; 54(7):1009-13. PubMed ID: 15951551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment.
    Chan HL; Wong ML; Hui AY; Chim AM; Tse AM; Hung LC; Chan FK; Sung JJ
    World J Gastroenterol; 2003 Dec; 9(12):2695-7. PubMed ID: 14669315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy.
    Yeo W; Steinberg JL; Tam JS; Chan PK; Leung NW; Lam KC; Mok TS; Johnson PJ
    J Med Virol; 1999 Nov; 59(3):263-9. PubMed ID: 10502254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.
    Lampertico P; Del Ninno E; Viganò M; Romeo R; Donato MF; Sablon E; Morabito A; Colombo M
    Hepatology; 2003 Apr; 37(4):756-63. PubMed ID: 12668967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B.
    Saruc M; Ozden N; Turkel N; Ayhan S; Hock LM; Tuzcuoglu I; Yuceyar H
    J Pharm Sci; 2003 Jul; 92(7):1386-95. PubMed ID: 12820143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum beta2-microglobulin levels in hepatitis B e antigen-negative chronic hepatitis B patients under long term lamivudine monotherapy: relationship with virological breakthrough.
    Elefsiniotis IS; Scarmeas N; Glynou I; Pantazis KD; Kada H; Mavrogiannis C
    Can J Gastroenterol; 2004 May; 18(5):307-13. PubMed ID: 15152280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferon treatment in hepatitis B surface antigen-positive hepatitis B e antibody-positive chronic hepatitis B: role of hepatitis B core antibody IgM titre in patient selection and treatment monitoring.
    Lobello S; Lorenzoni U; Vian A; Floreani A; Brunetto MR; Chiaramonte M
    J Viral Hepat; 1998 Jan; 5(1):61-6. PubMed ID: 9493518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short-term lamivudine for the treatment of chronic hepatitis B.
    Yotsuyanagi H; Yasuda K; Iino S
    Intervirology; 2003; 46(6):367-72. PubMed ID: 14688454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lamivudine treatment in maternally transmitted chronic hepatitis B virus infection patients.
    Ni YH; Huang FC; Wu TC; Kong MS; Jeng YM; Chen PJ; Tsuei DJ; Chen HL; Hsu HY; Chang MH
    Pediatr Int; 2005 Aug; 47(4):372-7. PubMed ID: 16091071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy.
    Zöllner B; Schäfer P; Feucht HH; Schröter M; Petersen J; Laufs R
    J Med Virol; 2001 Dec; 65(4):659-63. PubMed ID: 11745928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.